Information  X 
Enter a valid email address

Antisoma plc (SRC)

  Print      Mail a friend       Annual reports

Thursday 11 November, 2010

Antisoma plc

Antisoma announces outcome of ASA404 ATTRACT-2 ...

11 November 2010, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC:
ATSMY) announces that a scheduled interim analysis showed that the ATTRACT-2
trial should stop as ASA404 was unlikely to provide any benefit as a second-line
treatment for non-small cell lung cancer.

Glyn Edwards, CEO of Antisoma, said: "The findings from ATTRACT-2 mirror those
from ATTRACT-1 and therefore come as no surprise. Our focus for some time has
been on other programmes, most notably AS1413, which reports phase III data in
the first half of next year."


 Glyn Edwards, CEO

 Daniel Elger, VP Marketing & Communications    +44 (0)7909 915 068

 Antisoma plc

 Mark Court/Jessica Fontaine                    +44 (0)20 7466 5000

 Buchanan Communications

Except for the historical information presented, certain matters discussed in
this announcement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.

About the ATTRACT studies in non-small cell lung cancer (NSCLC)
ATTRACT-2 was a pivotal study carried out by Novartis to evaluate ASA404 in
previously treated, advanced NSCLC. Patients were randomised to receive either
ASA404 plus docetaxel or a placebo plus docetaxel as a control. A separate
study, ATTRACT-1, had investigated ASA404 as a first-line treatment for NSCLC.

About ASA404
ASA404 (vadimezan, formerly known as DMXAA and AS1404) is a small-molecule
Tumour-Vascular Disrupting Agent (Tumour-VDA) which targets the blood vessels
that nourish tumours. The drug was discovered by Professors Bruce Baguley and
William Denny and their teams at the Auckland Cancer Society Research Centre,
University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer
Research Ventures Limited (now Cancer Research Technology), the development and
commercialisation company of the Cancer Research Campaign (now Cancer Research
UK), in 2001. Worldwide rights to the drug were licensed to Novartis AG in April

About Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visit for further information
about Antisoma.


This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
Source: Antisoma plc via Thomson Reuters ONE